The Challenge
The traditionally long, expensive drug discovery process.
The AI Solution
End-to-end generative AI platform for drug design and discovery – from identifying novel targets to generating molecule structures and predicting their properties.
Type of AI Used: Generative AI (for molecule generation) and Deep Learning
Results & Impact
In 2023, Insilico's AI-designed drug for pulmonary fibrosis became the world's first AI-discovered medicine to enter Phase II trials. Moved from project start to Phase I in under 30 months (vs. ~5+ years traditionally).
